keyword
MENU ▼
Read by QxMD icon Read
search

Neutropenia

keyword
https://www.readbyqxmd.com/read/29236209/adverse-events-under-tacrolimus-and-cyclosporine-in-the-first-3-years-post-renal-transplantation-in-children
#1
Pauline Lancia, Beate Aurich, Phuong Ha, Anne Maisin, Véronique Baudouin, Evelyne Jacqz-Aigrain
BACKGROUND: Progress in immunosuppression has reduced acute rejection, graft loss and mortality after renal transplantation. Adverse drug reactions are well described in adults but few data are available in children. Our objectives were to analyse the adverse events reported in the first 3 years post-transplantation in children receiving tacrolimus or cyclosporine-based immunosuppression and compare them with the information of the Summary of Product Characteristics. METHODS: This retrospective study included all children who underwent a renal transplant at Hospital Robert Debré between 2002 and 2015...
December 13, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29233821/activity-of-the-pi3k-%C3%AE-%C3%AE-inhibitor-duvelisib-in-a-phase-i-trial-and-preclinical-models-of-t-cell-lymphoma
#2
Steven M Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison Moskowitz, Megan Perez, Patricia Myskowski, Adam Officer, Jacob D Jaffe, Sara N Morrow, Kerstin Allen, Mark Douglas, Howard Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C Aster, David Weaver, Francine M Foss, David M Weinstock
Duvelisib (IPI-145) is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-δ/γ isoforms currently in clinical development. PI3K-δ/γ inhibition may directly inhibit malignant T-cell growth, making Duvelisib a promising candidate for patients with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma. Inhibition of either isoform may also contribute to clinical responses by modulating nonmalignant immune cells. We investigated these dual effects in a TCL cohort from a Phase 1, open-label study of Duvelisib in patients with relapsed or refractory PTCL [n=16] and CTCL [n=19], along with in vitro and in vivo models of TCL...
December 12, 2017: Blood
https://www.readbyqxmd.com/read/29233611/analysis-of-factors-associated-with-in-hospital-mortality-in-lung-cancer-chemotherapy-patients-with-neutropenia
#3
REVIEW
Julia Cupp, Eva Culakova, Marek S Poniewierski, David C Dale, Gary H Lyman, Jeffrey Crawford
Lung cancer, compared with other solid tumors, is associated with high mortality rates from febrile neutropenia. The risk factors associated with in-hospital mortality were identified and compared for patients with lung cancer and patients with other solid tumors. Hospitalization data from the University Health Consortium database inclusive of 2004 to 2012 were analyzed. The study population included all adult patients with solid tumors who developed neutropenia. Cancer type, the presence of neutropenia, and further subgroups were determined using International Classification of Diseases, 9th revision, Clinical Modification codes...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29232172/halo-202-randomized-phase-ii-study-of-pegph20-plus-nab-paclitaxel-gemcitabine-versus-nab-paclitaxel-gemcitabine-in-patients-with-untreated-metastatic-pancreatic-ductal-adenocarcinoma
#4
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, Tara E Seery, William P Harris, Darren S Sigal, Fadi Braiteh, Paul S Ritch, Mark M Zalupski, Nathan Bahary, Paul E Oberstein, Andrea Wang-Gillam, Wilson Wu, Dimitrios Chondros, Ping Jiang, Sihem Khelifa, Jie Pu, Carrie Aldrich, Andrew E Hendifar
Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure and impairing perfusion. Preclinical studies demonstrated pegvorhyaluronidase alfa (PEGPH20) degrades HA, thereby increasing drug delivery. Patients and Methods Patients with previously untreated metastatic pancreatic ductal adenocarcinoma were randomly assigned to treatment with PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemcitabine (AG)...
December 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29231133/daratumumab-plus-bortezomib-melphalan-and-prednisone-for-untreated-myeloma
#5
María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Polina Kaplan, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna M Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Christopher Chiu, Jianping Wang, Robin Carson, Wendy Crist, William Deraedt, Huong Nguyen, Ming Qi, Jesus San-Miguel
Background The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. Methods In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression...
December 12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29230955/diagnostic-value-of-cell-bound-and-circulating-neutrophil-antibody-detection-in-pediatric-neutropenia
#6
Laura Porretti, Piero Farruggia, Federico Simone Colombo, Alessandra Cattaneo, Roberta Ghilardi, Nadia Mirra, Lucia Dora Notarangelo, Baldassarre Martire, Elena Trombetta, Silvano Milani, Claudia Vener, Paolo Rebulla
BACKGROUND: Chronic benign neutropenia of infancy includes primary autoimmune neutropenia (pAIN) and chronic idiopathic neutropenia (CIN). A diagnosis of CIN is supported by the absence of free and/or cell-bound neutrophil autoantibodies, which can be detected by flow cytometry with the indirect-granulocyte immunofluorescence test (I-GIFT) and direct-granulocyte immunofluorescence test (D-GIFT), respectively. Conclusive evidence is lacking on the diagnostic value of the D-GIFT, whose performance requires specific laboratory expertise, may be logistically difficult, and hampered by very low neutrophil count in patient samples...
December 12, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29230923/primary-antifungal-prophylaxis-decrease-of-invasive-fungal-disease-incidence-and-reduction-of-risk-factors-in-hematological-patients-in-a-5-year-retrospective-study
#7
Yan Li, Mingjuan Liu, Bing Zhai, Xiaoli Zhao, Lijun Wang, Honghua Li, Shuhong Wang, Haiyan Zhu, Quanshun Wang, Chunji Gao, Wenrong Huang, Li Yu
BACKGROUND: Invasive fungal disease (IFD) is a major cause of morbidity and mortality in patients with hematological malignancies. AIM: To evaluate the efficacy and rationality of primary antifungal prophylaxis (PAP) in a 5-year real life setting and choose an appropriate PAP strategy. METHODS: Clinical data of patients were retrospectively reviewed and IFD was diagnosed using the revised diagnostic criteria. The efficacy of PAP and the risk factors for IFD, especially the rationality of PAP, were evaluated...
December 12, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29230663/advantages-with-prophylactic-peg-rhg-csf-versus-rhg-csf-in-breast-cancer-patients-receiving-multiple-cycles-of-myelosuppressive-chemotherapy-an-open-label-randomized-multicenter-phase-iii-study
#8
Jie Xie, Jun Cao, Jing-Fen Wang, Bai-Hong Zhang, Xiao-Hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-Dong Wu, Qiang Yao, Xiao-Chun Zhao, Wei-Dong Mao, Ai-Mei Jiang, Shao-Shui Chen, Shun-E Yang, Shu-Sen Wang, Jian-Hong Wang, Yue-Yin Pan, Bi-Yong Ren, Yan-Ju Chen, Li-Zhi Ouyang, Kai-Jian Lei, Jing-Hua Gao, Wen-He Huang, Zhan Huang, Tao Shou, Yan-Ling He, Jing Cheng, Yang Sun, Wei-Ming Li, Shu-de Cui, Xin Wang, Zhi-Guo Rao, Hu Ma, Wei Liu, Xue-Yong Wu, Wei-Xi Shen, Fei-Lin Cao, Ze-Min Xiao, Biao Wu, Shu-Yan Tian, Dong Meng, Peng Shen, Bi-Yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Xi-Chun Hu
BACKGROUND: PEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China's registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy. METHODS: In this open-label, randomized, multicenter phase 3 study, breast cancer patients (n = 569) were randomized to receive PEG-rhG-CSF 100 µg/kg, PEG-rhG-CSF 6 mg, or rhG-CSF 5 µg/kg/d after chemotherapy...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29230661/weak-circadian-rhythm-increases-neutropenia-risk-among-breast-cancer-patients-undergoing-adjuvant-chemotherapy
#9
Wentao Li, Carol Chi-Hei Kwok, Dominic Chun-Wan Chan, Feng Wang, Lap Ah Tse
PURPOSE: Severe neutropenia is a common dose-limiting side effect of adjuvant breast cancer chemotherapy. We aimed to test the hypothesis that weak circadian rhythm is associated with an increased risk of neutropenia using a cohort study. METHODS: We consecutively recruited 193 breast cancer patients who received adjuvant chemotherapy (5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel; doxorubicin and cyclophosphamide; docetaxel and cyclophosphamide)...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29228994/survival-and-prognostic-factors-of-non-small-cell-lung-cancer-patients-with-postoperative-locoregional-recurrence-treated-with-radical-radiotherapy
#10
Li Ma, Bo Qiu, Jun Zhang, Qi-Wen Li, Bin Wang, Xu-Hui Zhang, Meng-Yun Qiang, Zhao-Lin Chen, Su-Ping Guo, Hui Liu
BACKGROUND: Locoregional recurrence remains the challenge for long-term survival of non-small cell lung cancer (NSCLC) patients after radical surgery, and curative-intent radiotherapy could be a treatment choice. This study aimed to assess the survival and prognostic factors of patients with postoperative locoregionally recurrent NSCLC treated with radical radiotherapy. METHODS: We reviewed medical records of 74 NSCLC patients with postoperative locoregional recurrence who received radical radiotherapy between April 2012 and February 2016 at Sun Yat-sen University Cancer Center (Guangzhou, China)...
December 11, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/29228331/clinical-characteristics-and-outcomes-of-patients-with-chronic-disseminated-candidiasis-who-need-adjuvant-corticosteroid-therapy
#11
Young-Rock Jang, Min-Chul Kim, Taeeun Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Jun Hee Woo, Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Sung-Han Kim
We performed a retrospective study involving 21 patients with chronic disseminate candidiasis (CDC) and 38 patients with candidemia. Neutropenia of >2 weeks' duration was more common in those with CDC (71%) than in those with candidemia (26%, P < .001), and the azole-resistant rate in patients with CDC (5%) was lower than that in those with candidemia (29%, P = .03). Of the 21 patients with CDC, five (24%) needed adjuvant corticosteroid therapy due to persistent debilitating fever (median, 19 days). Rapid defervescence (median, 5 days) occurred after adjuvant corticosteroid therapy...
December 8, 2017: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/29227817/comparing-granulocyte-colony-stimulating-factor-filgrastim-and-pegfilgrastim-to-its-biosimilars-in-terms-of-efficacy-and-safety-a-meta-analysis-of-randomised-clinical-trials-in-breast-cancer-patients
#12
Edoardo Botteri, Andriy Krendyukov, Giuseppe Curigliano
BACKGROUND: Granulocyte colony-stimulating factors (G-CSFs) are widely used to prevent neutropenia in cancer patients undergoing myelosuppressive chemotherapy. Several biosimilar medicines of G-CSF are now available, with their development involving a step-wise series of comparisons to demonstrate similarity to reference biologics. Randomised clinical trials (RCTs) are considered confirmatory, and for G-CSF biosimilars, patients with breast cancer (BC) undergoing myelosuppressive chemotherapy are the most sensitive population in which to confirm similarity...
December 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29226797/axicabtagene-ciloleucel-car-t-cell-therapy-in-refractory-large-b-cell-lymphoma
#13
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin, John M Timmerman, Patrick J Stiff, Jonathan W Friedberg, Ian W Flinn, Andre Goy, Brian T Hill, Mitchell R Smith, Abhinav Deol, Umar Farooq, Peter McSweeney, Javier Munoz, Irit Avivi, Januario E Castro, Jason R Westin, Julio C Chavez, Armin Ghobadi, Krishna V Komanduri, Ronald Levy, Eric D Jacobsen, Thomas E Witzig, Patrick Reagan, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y Go
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. Methods In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine...
December 10, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29225263/a-phase-i-ii-study-for-dose-finding-and-to-investigate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-nk012-an-sn-38-incorporating-macromolecular-polymeric-micelle-in-patients-with-multiple-myeloma
#14
Masaki Ri, Kenshi Suzuki, Shinsuke Iida, Kiyohiko Hatake, Takaaki Chou, Masafumi Taniwaki, Noriko Watanabe, Tetsuji Tsukamoto
Objective Multiple myeloma (MM) is the second most common hematological cancer. An attempt to treat MM using a topoisomerase I inhibitor was made based on our previous non-clinical studies suggesting the usefulness of an SN-38 derivative. Our aim was to conduct a phase I/II study of NK012, a micelle-forming SN-38 conjugate, in patients with relapsed/refractory multiple myeloma (RRMM). Methods NK012 was administered at doses of 12-24 mg/m2 and the safety, pharmacokinetics and preliminary efficacy were evaluated...
December 8, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29224502/brentuximab-vedotin-with-chemotherapy-for-stage-iii-or-iv-hodgkin-s-lymphoma
#15
Joseph M Connors, Wojciech Jurczak, David J Straus, Stephen M Ansell, Won S Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J Savage, Nancy L Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier L Zinzani, David Cunningham, Andras Rosta, Neil C Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina A Jolin, Dirk Huebner, John Radford
Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee...
December 10, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29223992/controversies-regarding-use-of-myeloid-growth-factors-in-leukemia
#16
REVIEW
Jacqueline N Poston, Pamela S Becker
This review focuses on the data supporting the use of myeloid growth factors (MGFs) in patients being treated for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and hairy cell leukemia, for which neutropenia is a common complication of treatment. However, due to the lack of randomized trial data or conflicting results of clinical studies, comprehensive guidelines have been difficult to formulate. Moreover, to date, these diagnoses have not been addressed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MGFs...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223991/a-patient-risk-model-of-chemotherapy-induced-febrile-neutropenia-lessons-learned-from-the-anc-study-group
#17
REVIEW
Gary H Lyman, Marek S Poniewierski
Neutropenia and its complications, including febrile neutropenia (FN), represent major toxicities associated with cancer chemotherapy, resulting in considerable morbidity, mortality, and costs. The myeloid growth factors such as granulocyte colony-stimulating factor (G-CSF) have been shown to reduce the risk of neutropenia complications while enabling safe and effective chemotherapy dose intensity. Concerns about the high costs of these agents along with limited physician adherence to clinical practice guidelines, resulting in both overuse and underuse, has stimulated interest in models for individual patient risk assessment to guide appropriate use of G-CSF...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223990/myeloid-growth-factors-version-2-2017-nccn-clinical-practice-guidelines-in-oncology
#18
Jeffrey Crawford, Pamela Sue Becker, James O Armitage, Douglas W Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A Griffiths, Shannon Hough, Dwight D Kloth, David J Kuter, Gary H Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S Rugo, Ayman A Saad, Lee S Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L Burns, Lenora Pluchino
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29222650/taxane-platinum-and-5-fu-prior-to-chemoradiotherapy-benefits-patients-with-stage-iv-neck-node-positive-head-and-neck-cancer-and-a-good-performance-status
#19
Natalie M Lowe, Jonathan M Bernstein, Kathleen Mais, Kate Garcez, Lip W Lee, Andrew Sykes, David J Thomson, Jarrod J Homer, Catharine M West, Nicholas J Slevin
PURPOSE: The benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most. METHODS: A single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT...
December 8, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29222255/non-chemotherapy-drug-induced-neutropenia-key-points-to-manage-the-challenges
#20
REVIEW
Brian R Curtis
Non-chemotherapy idiosyncratic drug-induced neutropenia (IDIN) is a relatively rare but potentially fatal disorder that occurs in susceptible individuals, with an incidence of 2.4 to 15.4 cases per million population. Affected patients typically experience severe neutropenia within several weeks to several months after first exposure to a drug, and mortality is ∼5%. The drugs most frequently associated with IDIN include metamizole, clozapine, sulfasalazine, thiamazole, carbimazole, amoxicillin, cotrimoxazole, ticlopidine, and valganciclovir...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
keyword
keyword
13155
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"